William E Fantegrossi

8PUBLICATIONS
9CO-AUTHORS
Toxicology (incl. clinical toxicology)PsychopharmacologyGene and molecular therapyBiomolecular modelling and designCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 04, 2025
Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations.

Jack E Henningfield, Sandra D Comer, Matthew L Banks

|Sep 11, 2025
Effects of psychostimulants on locomotor activity in the BTBR T+ Itpr3tf/J mouse: implications for comorbid autism spectrum disorder and attention deficit hyperactivity disorder.

William E Fantegrossi, Hannah E Shaw, Stephen A Fagot

|Mar 06, 2025
Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder.

Harpreet Kaur, Sedat Karabulut, James W Gauld

|Sep 18, 2024
A "Furious" Effort to Develop Novel 3,4-Methylenedioxymethamphetamine-Like Therapeutics.

William E Fantegrossi, Brenda M Gannon

|Jan 25, 2024
Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents.

Hannah E Shaw, Dylan R Patel, Brenda M Gannon

|Aug 06, 2022
Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in male mice.

Catheryn D Wilson, Fang Zheng, William E Fantegrossi

Pageof 2

Frequent Collaborators

3 joint publications

Brenda M Gannon

1 joint publications

Ryoichi Fujiwara

1 joint publications

Chad R Johnson

1 joint publications

Matthew L Banks